iRIS serves oncology trials at Beth Israel Deaconess Medical Center, Boston Children's Hospital, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital, and other affiliated institutions.
Did you know that you can use iRIS Reports to track and manage your submissions? We’ve just added a guide to commonly used study team reports in the iRIS WIKI. These reports are broadly available to all study teams. Check it out here.
How do I access iRIS reports?
Study teams access reports by clicking on My Profile and selecting My Reports from the drop down. Please submit a ticket to iRIS-DFHCC if you do not have My Reports in your My Profile drop down.
Reviewers can access additional reports for their committee/board via the Reports widget on their review assistant dashboard.
Which reports are most helpful to study teams?
Master Report - List all Submissions and Documents attached to study (Excel)
This report can be helpful when managing regulatory files or preparing for an audit. It will show you all documents submitted in iRIS for each submission on a given protocol.
Estimated IRB Review Dates for Submissions Routed to SRC
Current State of All My Active Study Submissions in iRIS
Keep tabs on all pending submissions for your studies with this report! It will show you the status of all active submissions for your protocols and any pending sign offs.
Reviewer Details and Comments by Reviewers On Submissions
Run this report to find contact information for the reviewers on a submission and review any shared comments that reviewers made that were not sent back as conditions.
Can I schedule reports to be run automatically?
Yes! Please submit a ticket to the iRIS support team with the report name, desired schedule, and list of recipients. For instructions on how to submit a ticket, please click here.
REMINDER: 5/25 11am Office Hours
TOPICS:
NEW Changes to Phase I Order Set build process effective May 25, 2021.
When to use a Dose/Cohort Open/Close form vs. Amendment
Strategies for managing multiple amendment submissions
Please submit additional topics and questions in advance using the link below.
Oncology trials in Boston are a collaborative effort involving many from many institutions. iRIS represents an opportunity to streamline all of the processes involved, and move trials from submission to activation, and to our patients, more quickly. Please take advantage of all of the provided information and resources to help us make this system as efficient to use as possible.
Sincerely,
Jeffrey Meyerhardt, MD, MPH
Associate Director for Clinical Trials,
Dana-Farber/Harvard Cancer Center
Drew Memmott
Associate Director for Administration,
Dana-Farber/Harvard Cancer Center
Erica Woulf
Senior Director for Research Informatics Operations,
